公开(公告)号：US20190000854A1

公开(公告)日：2019-01-03

申请号：US15969181

申请日：2018-05-02

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Yaron ILAN ,  Doina Cosma ROMAN ,  Michael HAYDEN ,  Einat AMIT-ROMACH

IPC: A61K31/52 ,  A61K9/28 ,  A61K45/06 ,  A61K9/00 ,  A61K9/20

CPC classification number: A61K31/52 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2846 ,  A61K45/06 ,  A61P1/16 ,  A61K2300/00

Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.

公开(公告)号：US20150352144A1

公开(公告)日：2015-12-10

申请号：US14758603

申请日：2013-12-30

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD.

Inventor： Smadar COHEN ,  Yaron ILAN ,  Eyal SHTEYER ,  Ami BEN-YA'ACOV

IPC: A61K31/734 ,  A61K45/06 ,  A61K9/00 ,  A61K31/167

CPC classification number: A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.

Abstract translation: 本文公开了使用藻酸盐组合物，用于治疗，预防和/或减少肝毒性诱导的肝损伤的组合物，方法和用途，以及用于治疗可由肝毒性试剂治疗的医学病症，其中在之前施用藻酸盐组合物， 伴随，或暴露于肝毒性剂后不久。 还公开了包含肝毒性剂和藻酸盐组合物的药物组合物及其用于治疗由肝毒素治疗的医学病症的用途。

公开(公告)号：US20150335675A1

公开(公告)日：2015-11-26

申请号：US14758589

申请日：2013-12-30

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD.

Inventor： Smadar COHEN ,  Yaron ILAN ,  Eyal SHTEYER ,  Ami BEN-YA'ACOV

IPC: A61K31/734 ,  A61K45/06 ,  A61K31/167

CPC classification number: A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

Abstract: Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than −25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10−8 cm2/millisecond, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease, liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

Abstract translation: 包含藻酸盐，钠离子源和载体（例如药学上可接受的载体）的组合物，其特征在于藻酸盐链的缔合减少，因此通过以下至少一种：（i）弱于-25的ζ电位 mV，载体中浓度为0.5％（w / v）藻酸盐; 和（ii）载体中浓度为0.5％（w / v）藻酸盐的至少10-8cm 2 /毫秒的扩散系数。 还公开了利用组合物治疗炎症性肠病，肝损伤，疾病和病症的组合物和方法的用途，用于治疗由肝毒性剂治疗的医学病症，以及用于减少或预防肝损伤，包括由肝毒性引起的肝损伤 代理商

公开(公告)号：US20180099006A1

公开(公告)日：2018-04-12

申请号：US15837004

申请日：2017-12-11

Applicant: Hadasit Medical Research Services and Development Ltd. ,  B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University

Inventor： Smadar COHEN ,  Yaron ILAN ,  Eyal SHTEYER ,  Ami BEN-YA'ACOV

IPC: A61K31/734 ,  A61K45/06 ,  A61K9/00 ,  A61K31/167

CPC classification number: A61K31/734 ,  A61K9/0053 ,  A61K31/167 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.

公开(公告)号：US20170281739A1

公开(公告)日：2017-10-05

申请号：US15507383

申请日：2015-09-21

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Yaron ILAN

IPC: A61K38/57

CPC classification number: A61K38/57 ,  A61P1/16

Abstract: Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (AAT) deficiency, the method comprising administering to the subject a therapeutically effective amount of AAT.

公开(公告)号：US20160317570A1

公开(公告)日：2016-11-03

申请号：US15206280

申请日：2016-07-10

Applicant: Hadasit Medical Research Services and Development Ltd. ,  Ben-Gurion University of the Negev Research and Development Authority

Inventor： Yaron ILAN ,  Gadi LALAZAR ,  Eyal SHTEYER ,  Ami BEN-YA'ACOV ,  Smadar COHEN ,  Tsiona ELKAYAM

IPC: A61K31/738

CPC classification number: A61K31/738 ,  A61K31/734 ,  A61L27/20 ,  A61L31/042 ,  A61P1/16 ,  C08L5/04

Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.

Abstract translation: 本发明涉及在有需要的受试者中治疗肝脏疾病的方法。 更具体地，本发明的方法基于治疗有效量的至少一种生物相容性藻酸盐生物材料，其任何修饰以及它们的任何组合，优选全身施用。 本发明还提供了在患有肝脏障碍的受试者中维持血清白蛋白水平和/或降低血清AST和ALT的方法。 此外，本发明提供了使用本发明描述的藻酸盐生物材料减少患有肝脏疾病的受试者的损伤的肝组织中细胞凋亡和诱导细胞增殖的方法。